Phio Pharma Q2 net loss $4.1M; cash $13.0M; PH-762 Phase 1b completed

Phio Pharmaceuticals Corp.

Net loss of $4.1M for Q2 2026 vs $2.2M in Q2 2025, driven by higher R&D spend.
Cash and equivalents $13.0M at June 30, 2026, down from $21.0M at Dec 31, 2025.
R&D expenses $3.1M in Q2, up 187% YoY on nonclinical toxicology and CMC costs.
Phase 1b trial of PH-762 completed; FDA meeting requested in Q3 2026 for next steps.
Established ATM equity offering up to $6.36M in April 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.